Escitalopram to Placebo in Patients With Localized Pancreatic Cancer (NCT05289830) | Clinical Trial Compass
TerminatedPhase 2
Escitalopram to Placebo in Patients With Localized Pancreatic Cancer
Stopped: Slow accrual
United States4 participantsStarted 2022-08-05
Plain-language summary
Use of antidepressants for participants with localized pancreatic and periampullary cancer receiving neoadjuvant therapy.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Subjects must have histologically or cytologically confirmed localized or locally advanced pancreatic ductal adenocarcinoma or other periampullary adenocarcinoma (bile duct, duodenal, ampullary)
✓. Subjects must not currently be on an antidepressant, anti-anxiety, anti-bipolar, or anti-psychotic medicine
✓. Aged 18-80 years.
✓. ECOG PS (Eastern Cooperative Oncology Group Performance Status) score of 0-2
✓. Planned to have at least 12 weeks of neoadjuvant chemotherapy as standard of care cancer treatment
✓. No diagnosis of bipolar disease
✓. Willing to comply with all study procedures and be available for the duration of the study
✓. Subjects must be mentally competent and must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
✕. Patients under the age of 18 or over 80
✕. Metastatic pancreatic or other periampullary cancer
✕. Resection of pancreatic cancer within the past year prior to study enrollment or planned surgery within the next 12 weeks.
✕. Currently on an antidepressant, anti-anxiety, anti-bipolar or anti-psychotic medicine. Patients who have taken MAOIs (Monoamine Oxidase Inhibitors) within the past 6 months are excluded.